Known for his pioneering work in the surgical management of prostate cancer and the physiology and pharmacology of benign prostatic disorders, Dr. Lepor is cofounder of Reviews in Urology. He is Professor and Martin Spatz Chairperson of Urology and Professor of Pharmacology at New York University School of Medicine in New York, NY.
Dr. Albala is Chief of Urology at Crouse Hospital in Syracuse, NY, and Medical Director for Associated Medical Professionals (a group of 29 urologists). He is considered a national and international authority in laparoscopic and robotic urologic surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urologic surgery. In addition, other clinical interests include minimally invasive treatment of benign prostatic hypertrophy and the use of fibrin sealants in surgery. Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Peña, Secretary of Transportation, on classified and unclassified public health-related issues.
Professor and Director of Pediatric Urology at New York University School of Medicine, Dr. Shapiro is known for her contributions to pediatric urology, especially in the area of fetal bladder, prostate, and urethral development. She recently served on the American Urological Association Guideline Panel for Vesicoureteral Reflux.
Neal D. Shore, MD, FACS, is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of the Society of Urologic Oncology Board, the Society of Urologic Oncology Clinical Trials Consortium (Secretary-Treasurer), and the Bladder Cancer Advocacy Network. He is the current President of LUGPA. He is a founder of both the CUSP Clinical Trials Consortium, and for DASHKO, a urology data registries consortium. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee; he is currently a member of the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank. He serves on the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, and as Editor of Everyday Urology. He has more than 125 peer-reviewed publications and numerous book chapters.
An internationally recognized leader in all aspects of managing patients with nephrolithiasis, Dr. Assimos is Chair of the Department of Urology at the University of Alabama at Birmingham School of Medicine. He is a member of the American Urological Association Nephrolithiasis Guidelines Committee and is currently conducting clinical and basic science research on oxalate metabolism.
A leading urologic oncologist with expertise in drug development and clinical trials, immunotherapy, and targeted therapy for genitourinary cancers, Dr. Belldegrun is the Director of the Institute of Urologic Oncology at the University of California, Los Angeles (UCLA), Professor and Chief of Urologic Oncology, and the Doumani Chair in Urologic Oncology at The David Geffen School of Medicine at UCLA in Los Angeles, CA.
The recipient of a Urologic Oncology Fellowship at the University of Texas M. D. Anderson Center, Dr. Brown is one of few fellowship-trained urologic oncologists in his region. His expertise is in the diagnosis and treatment of urologic cancers, using both minimally invasive (robot-assisted) and traditional techniques. Dr. Brown is a member of the American Urologic Association, American Society of Clinical Oncology, American Association of Cancer Research, and the Society of Urologic Oncology, as well as the author of numerous publications.
A recognized expert in female pelvic medicine and reconstructive surgery, urodynamics, incontinence, and voiding dysfunction in men and women, Dr. Brucker has authored numerous peer-reviewed articles and book chapters on these subjects, and was an associate editor of Vaginal Surgery for the Urologist. Dr. Brucker is an Assistant Professor of Urology at New York University Langone Medical Center, where he serves as the Director Neurourology at the Multiple Sclerosis Comprehensive Care Center.
Michael B. Chancellor, MD, is Professor of Urology and Director of Neurourology Program in the Department of Urology at the Oakland University William Beaumont School of Medicine in Royal Oak, MI. Dr. Chancellor has written more than 600 book chapters and peer-reviewed articles in journals, including the Journal of Urology, Urology, Gene Therapy, and The Lancet. He has also written 11 books and serves on the editorial board of 12 scientific journals. Dr. Chancellor has gained national and international recognition in the areas of stem cell and tissue engineering and drug discovery. He was the first urologist to use botulinum toxin to treat lower urinary tract dysfunction.
Dr. Concepcion is the current director of The Advanced Therapeutic Center of Urology Associates in Nashville, TN. His clinical interests are lower urinary tract reconstruction and management of the advanced prostate cancer patient. He is a member of American Urologic Association, Asian Congress of Urology, American College of Surgeons, and Society of Urologic Oncology. He has served as President of LUGPA and a current national board member of ZERO, the project to end prostate cancer.
A recognized authority on benign disease of the prostate and female urology, Dr. Kaplan is E Darracott Vaughan Jr Professor of Urology and Director, Iris Cantor Men’s Health Center at Weill Cornell Medical College of Cornell University in New York, NY. Dr. Kaplan is on the editorial boards of Urology and the Journal of Urology, and has authored more than 700 articles.
Dr. Kassabian is the Research Director and Medical Director of Georgia Urology, P.A., one of the largest and well known private practice urology groups in the country. Dr. Kassabian has written numerous publications, articles, and book chapters, has made presentations at both national and international meetings, and has lectured extensively on prostate cancer and prostate diseases. Dr. Kassabian is fellowship trained in urologic oncology and performs clinical research, especially in prostate disease. He is also interested in major open oncologic surgeries, including urinary diversion. Dr. Kassabian is a member of the American Urologic Association, the southeastern section of the American Urology Association, the Canadian Urological Association, the Societe Internationale d’Urologie, and the Society of Urologic Oncology.
An internationally recognized expert in prostate cancer, Dr. Loeb is a graduate of the Johns Hopkins urology residency program and subsequently received a Masters degree in Comparative Effectiveness Research at New York University (NYU). Dr. Loeb is currently an Assistant Professor of Urology and Population Health at NYU and the Manhattan Veterans Affairs Hospital. She has authored more than 260 publications and numerous book chapters on prostate cancer, and hosts the Men’s Health Show on Sirius XM 110. Dr. Loeb also serves on the editorial boards of BJU International, European Urology, Urology Practice, Nature Reviews Urology, and Urology Times.
An authority on male reproductive medicine and surgery, Dr. Meacham is program director of the Rocky Mountain Urological Society. He also serves as co-moderator of Androlog, an internet-based group for clinicians and scientists involved in the diagnosis and treatment of male infertility. Dr. Meacham is Professor, Residency Program Director, and Head of the Division of Urology at the University of Colorado School of Medicine in Denver, CO.
A respected researcher in the fields of inflammatory diseases of the urinary tract and benign diseases of the prostate, Dr. Nickel is Professor of Urology at Queen’s University in Kingston, Ontario, Canada, and Canadian Institutes of Health Research Canada Research Chair in Urologic Pain and Inflammation. He directs the Prostatitis and Interstitial Cystitis Clinical Research Center and BPH Clinical Research at the Centre for Applied Urological Research, Kingston.
A prominent researcher on benign prostatic hyperplasia and prostate cancer, with a current focus on new prostate cancer serum markers, Dr. Partin is the David Hall McConnell Professor and Director of Urology at The Johns Hopkins Medical Institutions and The Johns Hopkins Hospital in Baltimore, MD. He is also the editor of Campbell-Walsh Urology.
David F. Penson, MD, MPH is the Hamilton and Howd Chair in Urologic Oncology, Professor of Urologic Surgery and Medicine and Director of the Center for Surgical Quality and Outcomes Research at Vanderbilt University. His general research focus is clinical epidemiology and health services research across all urologic diseases, and his specific interests include the comparative effectiveness of treatment options in localized prostate cancer and the impact of the disease and its treatment on patients’ quality of life. He has received federal grant funding from the National Cancer Institute, the US Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, and the Patient-Centered Outcomes Research Institute. He became the Chair of the American Urological Association’s Health Policy Council in June 2012 and has also served on the National Quality Forum, the Cancer Quality Alliance, and the American College of Surgeons Commission on Cancer.
Recognized for his work in the areas of male infertility and erectile dysfunction, Dr. Rajfer is Professor of Urology in the Department of Urology at the University of California at Los Angeles (UCLA). He is also Chief of Urology at Harbor-UCLA Medical Center in Torrance, CA.
A clinician and researcher recognized for his contributions to the study of benign and malignant prostate diseases, Dr. Roehrborn is Professor and Chairman of the Department of Urology at The University of Texas Southwestern Medical Center at Dallas. He is on multiple editorial boards, is Associate Editor of Urology, and author of more than 300 peer-reviewed publications, mostly in the field of prostatic diseases.
Dr. Rubenstein is Chief Compliance Officer at Chesapeake Urology Associates and Clinical Associate Professor in the Department of Surgery at University of Maryland School of Medicine. In addition to his regular urology practice, he has subspecialty training in minimally invasive surgery, metabolic evaluation, and treatment of kidney stones. Dr. Rubenstein works with pediatric patients and performs circumcisions and circumcision revisions, and diagnoses and treats undescended testicle, hernia, and enuresis. He has been published in a number of medical journals and has received numerous achievement awards.
With a combined focus on prostate disease research and treatment, Dr. Slawin is founder and Director of the Vanguard Urologic Institute and the Texas Prostate Center in Houston, TX. He is a member of the Center for Clinical and Translational Sciences at the University of Texas Health Science Center at Houston, Clinical Professor of Urology at Baylor College of Medicine, and Director of Urology at Memorial Hermann Hospital, Texas Medical Center.
Dr. Williams has both a research fellowship and a clinical fellowship in urologic oncology from the M.D. Anderson Cancer Center in Houston, TX. Dr. Williams is a member of the American Association for Cancer Research, the Society of Urologic Oncology, the American Society of Clinical Oncology, the American Association of Clinical Urologists, and the American Urological Association. Dr. Williams served as a clinical specialist in the Department of Urology at M.D. Anderson Cancer Center, and is currently an assistant professor in the Department of Urology at Eastern Virginia Medical School. His primary clinical interests are in advanced prostate cancer, bladder cancer, and local and advanced kidney cancer.